ArticleThe Journal of allergy and clinical immunology2020

Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.

Hailan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.